Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I Study
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
UNLABELLED: The alpha-emitter (211)At labeled to a monoclonal antibody has proven safe and effective in treating microscopic ovarian cancer in the abdominal cavity of mice. Women in complete clinical remission after second-line chemotherapy for recurrent ovarian carcinoma were enrolled in a phase I study. The aim was to determine the pharmacokinetics for assessing absorbed dose to normal tissues and investigating toxicity. METHODS: Nine patients underwent laparoscopy 2-5 d before the therapy; a peritoneal catheter was inserted, and the abdominal cavity was inspected to exclude the presence of macroscopic tumor growth or major adhesions. (211)At was labeled to MX35 F(ab')(2) using the reagent N-succinimidyl-3-(trimethylstannyl)-benzoate. Patients were infused with (211)At-MX35 F(ab')(2) (22.4-101 MBq/L) in dialysis solution via the peritoneal catheter. gamma-Camera scans were acquired on 3-5 occasions after infusion, and a SPECT scan was acquired at 6 h. Samples of blood, urine, and peritoneal fluid were collected at 1-48 h. Hematology and renal and thyroid function were followed for a median of 23 mo. RESULTS: Pharmacokinetics and dosimetric results were related to the initial activity concentration (IC) of the infused solution. The decay-corrected activity concentration decreased with time in the peritoneal fluid to 50% IC at 24 h, increased in serum to 6% IC at 45 h, and increased in the thyroid to 127% +/- 63% IC at 20 h without blocking and less than 20% IC with blocking. No other organ uptakes could be detected. The cumulative urinary excretion was 40 kBq/(MBq/L) at 24 h. The estimated absorbed dose to the peritoneum was 15.6 +/- 1.0 mGy/(MBq/L), to red bone marrow it was 0.14 +/- 0.04 mGy/(MBq/L), to the urinary bladder wall it was 0.77 +/- 0.19 mGy/(MBq/L), to the unblocked thyroid it was 24.7 +/- 11.1 mGy/(MBq/L), and to the blocked thyroid it was 1.4 +/- 1.6 mGy/(MBq/L) (mean +/- SD). No adverse effects were observed either subjectively or in laboratory parameters. CONCLUSION: This study indicates that by intraperitoneal administration of (211)At-MX35 F(ab')(2) it is possible to achieve therapeutic absorbed doses in microscopic tumor clusters without significant toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., & Bunn, P. A. (1984) · Journal of Immunological Methods · doi:10.1016/0022-1759(84)90435-6 · Cited by 943
Bolch, W. E., Eckerman, K. F., Sgouros, G., & Thomas, S. R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.056036 · Cited by 913
Targeted α particle immunotherapy for myeloid leukemia
Jurcic, J. G., Larson, S. M., Sgouros, G., McDevitt, M. R., Finn, R. D., Divgi, C. R., Ballangrud, Å. M., Hamacher, K. A., Ma, D., Humm, J. L., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1233.h81602001233_1233_1239 · Cited by 472
Self-citationZalutsky, M. R., Reardon, D. A., Akabani, G., Coleman, R. E., Friedman, A. H., Friedman, H. S., McLendon, R. E., Wong, T. Z., & Bigner, D. D. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.046938 · Cited by 410
Bone marrow dosimetry for radioimmunotherapy: theoretical considerations.
Sgouros, G. (1993) · PubMed · Cited by 303
Verheijen, R. H., Massuger, L. F., Benigno, B. B., Epenetos, A. A., Lopes, A., Soper, J. T., Markowska, J., Vyzula, R., Jobling, T., Stamp, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5973 · Cited by 193
Intraperitoneal Radioimmunotherapy of Ovarian Cancer with177Lu-CC49: A Phase I/II Study
Alvarez, R. D., Partridge, E. E., Khazaeli, M. B., Plott, G., Austin, M., Kilgore, L. C., Russell, C. D., Liu, T., Grizzle, W. E., Schlom, J., et al. (1997) · Gynecologic Oncology · doi:10.1006/gyno.1996.4577 · Cited by 181
Lindegren, S., Bäck, T. A., & Jensen, H. J. (2001) · Applied Radiation and Isotopes · doi:10.1016/s0969-8043(01)00044-6 · Cited by 161
Self-citationStewart, J. S. W., Hird, V., Snook, D. E., Sullivan, M. H. F., Hooker, G., Courtenay-Luck, N. S., Sivolapenko, G. B., Griffiths, M., Myers, M. J., Lambert, H. E., et al. (1989) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(89)90337-4 · Cited by 108
Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.
Meredith, R. F., Partridge, E. E., Alvarez, R. D., Khazaeli, M. B., Plott, G., Russell, C. D., Wheeler, R. H., Liu, T., Grizzle, W. E., Schlom, J., et al. (1996) · PubMed · Cited by 107
Crippa, F., Bolis, G., Seregni, E. C., Gavoni, N., Scarfone, G., Ferraris, C., Buraggi, G. L., & Bombardieri, E. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(94)00454-d · Cited by 93
Palm, S., Bäck, T. A., Claesson, I., Danielsson, A., Elgqvist, J., Frost, S. H. L., Hultborn, R., Jensen, H. J., Lindegren, S., & Jacobsson, L. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.06.023 · Cited by 76
Self-citationElgqvist, J., Andersson, H., Bäck, T. A., Hultborn, R., Jensen, H. J., Karlsson, B., Lindegren, S., Palm, S., Warnhammar, E., & Jacobsson, L. (2005) · PubMed · Cited by 72
Self-citationElgqvist, J., Andersson, H., Bäck, T. A., Claesson, I., Hultborn, R., Jensen, H. J., Johansson, B. R., Lindegren, S., Olsson, M., Palm, S., et al. (2006) · PubMed · Cited by 68
Self-citationAndersson, H., Lindegren, S., Bäck, T. A., Jacobsson, L., Leser, G., & Horváth, G. (2000) · PubMed · Cited by 56
Self-citationBuijs, W. C. A. M., Tibben, J. G., Boerman, O. C., Molthoff, C. F. M., Massuger, L. F. A. G., Koenders, E. B., Schijf, C. P. T., Siegel, J. A., & Corstens, F. H. M. (1998) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050335 · Cited by 48
Andersson, H., Palm, S., Lindegren, S., Bäck, T. A., Jacobsson, L., Leser, G., & Horváth, G. (2001) · PubMed · Cited by 48
Self-citationHåkan Andersson, S. L. (2000) · Acta Oncologica · doi:10.1080/028418600750063820 · Cited by 42
Elgqvist, J., Andersson, H., Bäck, T. A., Claesson, I., Hultborn, R., Jensen, H. J., Lindegren, S., Olsson, M., Palm, S., Warnhammar, E., et al. (2006) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.07.009 · Cited by 39
Self-citationHindorf, C., Lind�n, O., Tennvall, J., et al. (2002) · Cancer · doi:10.1002/cncr.10291 · Cited by 18
Determination of Inulin, Albumin and Erythrocyte Spaces in the Bone Marrow of Rabbits
Michelsen, K. (1969) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1969.tb04550.x · Cited by 13
Cited by
An overview of targeted alpha therapy
Kim, Y.-S., & Brechbiel, M. W. (2012) · Tumor Biology · doi:10.1007/s13277-011-0286-y · Cited by 278
The elements of life and medicines
Chellan, P., & Sadler, P. J. (2015) · Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences · doi:10.1098/rsta.2014.0182 · Cited by 274
Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications.
Nelson, B. J. B., Andersson, J. D., & Wuest, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010049 · Cited by 194
Development of targeted alpha particle therapy for solid tumors.
Tafreshi, N. K., Doligalski, M. L., Tichacek, C. J., Pandya, D. N., Budzevich, M. M., El-Haddad, G., Khushalani, N. I., Moros, E. G., McLaughlin, M. L., Wadas, T. J., et al. (2019) · Molecules · doi:10.3390/molecules24234314 · Cited by 157
“211At NaPi2b MX35 F(ab′)2 211At-MX35 F(ab′)2 Ovarian carcinoma Phase I/9 Intraperitoneal No adverse effects, grade I toxicity, no bone marrow toxicity [239]”
BackgroundA nephron-based model of the kidneys for macro-to-micro α-particle dosimetry
Hobbs, R. F., Song, H., Huso, D. L., H Sundel, M., & Sgouros, G. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/13/4403 · Cited by 61
Metadata
- Authors
- Andersson, H., Cederkrantz, E., Bäck, T., Divgi, C., Elgqvist, J., Himmelman, J., Horvath, G., Jacobsson, L., Jensen, H., Lindegren, S., Palm, S., & Hultborn, R.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2009-06-12
- Volume
- 50
- Issue
- 7
- Pages
- 1153-1160
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2149171028
- Cited by
- 298
- References
- 21
- FWCI
- 11.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.